Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies

ABSTRACT:An evaluation of the leishmanicidal activity in vitro and in vivo of hypericin, an expanded-spectrum photosensitizer found in Hypericum perforatum, is presented. Hypericin was evaluated against intracellular amastigotes in vitro of Leishmania (Viannia) panamensis. A topical formulation cont...

Full description

Autores:
Montoya Cuervo, Edwin Andrés
Daza Figueredo, Juan Alejandro
Muñoz Herrera, Diana Lorena
Ríos Ramírez, Yesmit Karina
Taylor Orozco, Viviana Milena
Cedeño, David
Vélez Bernal, Iván Darío
Echeverri López, Luis Fernando
Robledo Restrepo, Sara María
Tipo de recurso:
Article of investigation
Fecha de publicación:
2015
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/32966
Acceso en línea:
https://hdl.handle.net/10495/32966
Palabra clave:
Antracenos
Anthracenes
Línea Celular
Cell Line
Cricetinae
Leishmania
Leishmaniasis Cutánea
Leishmaniasis, Cutaneous
Perileno
Perylene
Fotoquimioterapia
Photochemotherapy
Fármacos Fotosensibilizantes
Photosensitizing Agents
Células U937
U937 Cells
Cicatrización de Heridas
Wound Healing
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Description
Summary:ABSTRACT:An evaluation of the leishmanicidal activity in vitro and in vivo of hypericin, an expanded-spectrum photosensitizer found in Hypericum perforatum, is presented. Hypericin was evaluated against intracellular amastigotes in vitro of Leishmania (Viannia) panamensis. A topical formulation containing 0.5% hypericin was developed and assayed in vivo in a hamster model of cutaneous leishmaniasis. Results demonstrate that hypericin induces a significant antiamastigote effect in vitro against L. panamensis by decreasing the number of parasites inside infected cells. The topical formulation of 0.5% hypericin allows healing of L. pana- mensis-induced lesions upon a topical application of 40 mg/day plus visible-light irradiation (5 J/cm2, 15 min), twice a week for 3 weeks.